BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lyn-Cook BD, Yan-Sanders Y, Moore S, Taylor S, Word B, Hammons GJ. Increased levels of NAD(P)H: quinone oxidoreductase 1 (NQO1) in pancreatic tissues from smokers and pancreatic adenocarcinomas: A potential biomarker of early damage in the pancreas. Cell Biol Toxicol. 2006;22:73-80. [PMID: 16532285 DOI: 10.1007/s10565-006-0156-3] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 1.9] [Reference Citation Analysis]
Number Citing Articles
1 Siegel D, Reigan P, Ross D. One- and Two-Electron-Mediated Reduction of Quinones: Enzymology and Toxicological Implications. In: Elfarra A, editor. Advances in Bioactivation Research. New York: Springer; 2008. pp. 1-29. [DOI: 10.1007/978-0-387-77300-1_7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
2 Zheng Y, Pan D, Zhang Y, Zhang Y, Shen Y. Hemicyanine-based near-infrared fluorescent probe for the ultrasensitive detection of hNQO1 activity and discrimination of human cancer cells. Analytica Chimica Acta 2019;1090:125-32. [DOI: 10.1016/j.aca.2019.09.012] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
3 Jiang ZN, Ahmed SMU, Wang QC, Shi HF, Tang XW. Quinone oxidoreductase 1 is overexpressed in gastric cancer and associated with outcome of adjuvant chemotherapy and survival. World J Gastroenterol 2021; 27(22): 3085-3096 [PMID: 34168410 DOI: 10.3748/wjg.v27.i22.3085] [Reference Citation Analysis]
4 Michael M, Doherty MM. Drug metabolism by tumours: its nature, relevance and therapeutic implications. Expert Opin Drug Metab Toxicol 2007;3:783-803. [PMID: 18028025 DOI: 10.1517/17425255.3.6.783] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
5 Criddle DN, Gillies S, Baumgartner-Wilson HK, Jaffar M, Chinje EC, Passmore S, Chvanov M, Barrow S, Gerasimenko OV, Tepikin AV. Menadione-induced reactive oxygen species generation via redox cycling promotes apoptosis of murine pancreatic acinar cells. J Biol Chem. 2006;281:40485-40492. [PMID: 17088248 DOI: 10.1074/jbc.m607704200] [Cited by in Crossref: 222] [Cited by in F6Publishing: 127] [Article Influence: 13.9] [Reference Citation Analysis]
6 Bull LM, White DL, Bray M, Nurgalieva Z, El-Serag HB. Phase I and II enzyme polymorphisms as risk factors for Barrett's esophagus and esophageal adenocarcinoma: a systematic review and meta-analysis. Dis Esophagus 2009;22:571-87. [PMID: 19222528 DOI: 10.1111/j.1442-2050.2009.00947.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
7 Mohelnikova-Duchonova B, Marsakova L, Vrana D, Holcatova I, Ryska M, Smerhovsky Z, Slamova A, Schejbalova M, Soucek P. Superoxide dismutase and nicotinamide adenine dinucleotide phosphate: quinone oxidoreductase polymorphisms and pancreatic cancer risk. Pancreas 2011;40:72-8. [PMID: 20966810 DOI: 10.1097/MPA.0b013e3181f74ad7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
8 Alard A, Fabre B, Anesia R, Marboeuf C, Pierre P, Susini C, Bousquet C, Pyronnet S. NAD(P)H quinone-oxydoreductase 1 protects eukaryotic translation initiation factor 4GI from degradation by the proteasome. Mol Cell Biol 2010;30:1097-105. [PMID: 20028737 DOI: 10.1128/MCB.00868-09] [Cited by in Crossref: 28] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
9 Li LS, Bey EA, Dong Y, Meng J, Patra B, Yan J, Xie XJ, Brekken RA, Barnett CC, Bornmann WG, Gao J, Boothman DA. Modulating endogenous NQO1 levels identifies key regulatory mechanisms of action of β-lapachone for pancreatic cancer therapy. Clin Cancer Res 2011;17:275-85. [PMID: 21224367 DOI: 10.1158/1078-0432.CCR-10-1983] [Cited by in Crossref: 83] [Cited by in F6Publishing: 40] [Article Influence: 7.5] [Reference Citation Analysis]
10 Zhou L, Chen J, Sun Y, Chai K, Zhu Z, Wang C, Chen M, Han W, Hu X, Li R, Yao T, Li H, Dong C, Shi S. A self-amplified nanocatalytic system for achieving "1 + 1 + 1 > 3" chemodynamic therapy on triple negative breast cancer. J Nanobiotechnology 2021;19:261. [PMID: 34481495 DOI: 10.1186/s12951-021-00998-y] [Reference Citation Analysis]
11 Singh V, Upadhyay G, Rastogi N, Singh K, Singh MP. Polymorphism of xenobiotic-metabolizing genes and breast cancer susceptibility in North Indian women. Genet Test Mol Biomarkers 2011;15:343-9. [PMID: 21329464 DOI: 10.1089/gtmb.2010.0197] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
12 Beg MS, Huang X, Silvers MA, Gerber DE, Bolluyt J, Sarode V, Fattah F, Deberardinis RJ, Merritt ME, Xie XJ, Leff R, Laheru D, Boothman DA. Using a novel NQO1 bioactivatable drug, beta-lapachone (ARQ761), to enhance chemotherapeutic effects by metabolic modulation in pancreatic cancer. J Surg Oncol 2017;116:83-8. [PMID: 28346693 DOI: 10.1002/jso.24624] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
13 Chakrabarti G, Moore ZR, Luo X, Ilcheva M, Ali A, Padanad M, Zhou Y, Xie Y, Burma S, Scaglioni PP, Cantley LC, DeBerardinis RJ, Kimmelman AC, Lyssiotis CA, Boothman DA. Targeting glutamine metabolism sensitizes pancreatic cancer to PARP-driven metabolic catastrophe induced by ß-lapachone. Cancer Metab 2015;3:12. [PMID: 26462257 DOI: 10.1186/s40170-015-0137-1] [Cited by in Crossref: 75] [Cited by in F6Publishing: 70] [Article Influence: 10.7] [Reference Citation Analysis]
14 Hayes AJ, Skouras C, Haugk B, Charnley RM. Keap1-Nrf2 signalling in pancreatic cancer. Int J Biochem Cell Biol 2015;65:288-99. [PMID: 26117456 DOI: 10.1016/j.biocel.2015.06.017] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 4.3] [Reference Citation Analysis]
15 Li Z, Zhang Y, Jin T, Men J, Lin Z, Qi P, Piao Y, Yan G. NQO1 protein expression predicts poor prognosis of non-small cell lung cancers. BMC Cancer. 2015;15:207. [PMID: 25880877 DOI: 10.1186/s12885-015-1227-8] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 6.6] [Reference Citation Analysis]
16 Shokrzadeh M, Mohammadpour A, Ghassemi-barghi N, Hoseini V, Abediankenari S, Tabari YS. METALLOTHIONEIN-2A (RS1610216&RS28366003) GENE POLYMORPHISMS AND THE RISK OF STOMACH ADENOCARCINOMA. Arq Gastroenterol 2019;56:367-71. [DOI: 10.1590/s0004-2803.201900000-69] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
17 Booth DM, Mukherjee R, Sutton R, Criddle DN. Calcium and reactive oxygen species in acute pancreatitis: friend or foe? Antioxid Redox Signal. 2011;15:2683-2698. [PMID: 21861696 DOI: 10.1089/ars.2011.3983] [Cited by in Crossref: 45] [Cited by in F6Publishing: 44] [Article Influence: 4.1] [Reference Citation Analysis]
18 Lochan R, Daly AK, Reeves HL, Charnley RM. Genetic susceptibility in pancreatic ductal adenocarcinoma. Br J Surg 2008;95:22-32. [PMID: 18076020 DOI: 10.1002/bjs.6049] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
19 Awadallah NS, Dehn D, Shah RJ, Russell Nash S, Chen YK, Ross D, Bentz JS, Shroyer KR. NQO1 expression in pancreatic cancer and its potential use as a biomarker. Appl Immunohistochem Mol Morphol. 2008;16:24-31. [PMID: 18091324 DOI: 10.1097/pai.0b013e31802e91d0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 23] [Article Influence: 1.0] [Reference Citation Analysis]
20 Yang Y, Zhang Y, Wu Q, Cui X, Lin Z, Liu S, Chen L. Clinical implications of high NQO1 expression in breast cancers. J Exp Clin Cancer Res. 2014;33:14. [PMID: 24499631 DOI: 10.1186/1756-9966-33-14] [Cited by in Crossref: 87] [Cited by in F6Publishing: 86] [Article Influence: 10.9] [Reference Citation Analysis]
21 Yu H, Liu H, Wang LE, Wei Q. A functional NQO1 609C& gt; T polymorphism and risk of gastrointestinal cancers: a meta-analysis. PLoS One. 2012;7:e30566. [PMID: 22272361 DOI: 10.1371/journal.pone.0030566] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
22 Parkinson EI, Hergenrother PJ. Deoxynyboquinones as NQO1-Activated Cancer Therapeutics. Acc Chem Res 2015;48:2715-23. [PMID: 26444384 DOI: 10.1021/acs.accounts.5b00365] [Cited by in Crossref: 53] [Cited by in F6Publishing: 51] [Article Influence: 7.6] [Reference Citation Analysis]
23 Criddle DN, Gerasimenko JV, Baumgartner HK, Jaffar M, Voronina S, Sutton R, Petersen OH, Gerasimenko OV. Calcium signalling and pancreatic cell death: apoptosis or necrosis? Cell Death Differ. 2007;14:1285-1294. [PMID: 17431416 DOI: 10.1038/sj.cdd.4402150] [Cited by in Crossref: 109] [Cited by in F6Publishing: 111] [Article Influence: 7.3] [Reference Citation Analysis]
24 Lundberg AP, Francis JM, Pajak M, Parkinson EI, Wycislo KL, Rosol TJ, Brown ME, London CA, Dirikolu L, Hergenrother PJ, Fan TM. Pharmacokinetics and derivation of an anticancer dosing regimen for the novel anti-cancer agent isobutyl-deoxynyboquinone (IB-DNQ), a NQO1 bioactivatable molecule, in the domestic felid species. Invest New Drugs 2017;35:134-44. [PMID: 27975234 DOI: 10.1007/s10637-016-0414-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
25 Lin L, Qin Y, Jin T, Liu S, Zhang S, Shen X, Lin Z. Significance of NQO1 overexpression for prognostic evaluation of gastric adenocarcinoma. Exp Mol Pathol. 2014;96:200-205. [PMID: 24384455 DOI: 10.1016/j.yexmp.2013.12.008] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 3.3] [Reference Citation Analysis]